Binders Excipients Market by Type (Alginates, Cellulose Derivatives, Gums And Gels), Form (Dry Binder, Liquid Binder), Grade, Application - Global Forecast 2025-2032
Description
The Binders Excipients Market was valued at USD 1.99 billion in 2024 and is projected to grow to USD 2.18 billion in 2025, with a CAGR of 9.93%, reaching USD 4.24 billion by 2032.
An authoritative framing of binder excipients importance that situates formulation performance, process robustness, and regulatory imperatives within contemporary pharmaceutical development
Binder excipients play a foundational role in the manufacture and performance of solid dosage pharmaceuticals and nutraceuticals, providing mechanical cohesion, process stability, and controlled disintegration behavior. Their selection and optimization influence tablet tensile strength, friability, dissolution kinetics, and manufacturability across granulation and compression operations. As formulation strategies and production paradigms evolve, binders are no longer ancillary inputs but critical enablers of downstream performance, packaging choices, and patient experience.
In parallel, material science advances and changing regulatory expectations have elevated the technical bar for binder selection. Modern binder development balances multifunctionality, compatibility with active pharmaceutical ingredients, and robustness under continuous and direct-compression processes. Quality by design approaches demand deeper characterization of binder particle size distribution, moisture sorption, and flow properties, while sustainability concerns prompt evaluation of renewable sources and manufacturing footprints. This introduction sets the context for understanding how binders contribute to product differentiation and supply chain dynamics across therapeutic and nutraceutical portfolios.
How technological modernization, regulatory scrutiny, and sustainability priorities are converging to redefine binder excipient functionality and supplier relationships
The landscape for binder excipients is undergoing transformative shifts driven by technological, regulatory, and sustainability pressures that are reshaping formulation and manufacturing practices. Adoption of continuous manufacturing and intensified processes has raised demand for excipients with predictable rheology and tighter functional tolerances, prompting suppliers to invest in advanced characterization and engineering of binder particles. Meanwhile, the growing emphasis on direct compression routes has accelerated interest in multifunctional binders that simplify formulations by reducing auxiliary excipient counts and enabling higher throughput.
Concurrently, regulatory agencies are increasing focus on supply chain transparency, excipient provenance, and risk-based control strategies. This has nudged manufacturers toward more rigorous supplier qualification, enhanced batch-to-batch traceability, and earlier engagement with regulators for novel excipient introduction. Sustainability goals have also reframed raw material sourcing: formulators and procurement teams are evaluating bio-based polymers, lower-energy processing routes, and supply partners with demonstrable commitments to reducing carbon and water intensity. Together, these forces are creating a market in which performance attributes, environmental credentials, and supply chain resilience are equally weighted in binder selection decisions.
Assessment of how United States tariff dynamics in 2025 have reshaped supply strategies, procurement behavior, and formulation risk management across the binder excipient value chain
Tariff policy developments in the United States during 2025 have introduced a new layer of complexity for organizations that source binder excipients internationally. Increased import duties and related administrative measures have magnified landed cost volatility and prompted procurement teams to reassess supplier matrices and contractual terms. The cumulative effect has been a renewed focus on supply chain resilience, with firms weighing options such as nearshoring, multi-sourcing, and strategic stocking to mitigate exposure to tariff-driven cost swings.
Beyond cost implications, tariffs have affected sourcing timelines and inventory strategies. Companies with just-in-time replenishment models faced pressures to extend lead times or secure local alternatives to avoid disruption. In parallel, suppliers in exporting markets adjusted commercial behaviors, including renegotiating long-term contracts and reconfiguring logistics to preserve competitiveness. Formulation groups responded by prioritizing binder chemistries that are available from a broader set of qualified vendors, reducing single-source dependency. Strategic procurement workstreams now routinely integrate tariff scenario planning into supplier scorecards, and cross-functional teams are coordinating with regulatory affairs to ensure that any vendor or material substitutions align with quality and compliance expectations.
Segmentation-informed synthesis of binder types, application pathways, form factors, and grade distinctions that elucidates formulation and procurement decision drivers
Segmentation-driven insights reveal where technical demand and commercial opportunity intersect across binder excipients. When analyzed by type, formulations increasingly rely on Alginates for specific controlled-release and mucoadhesive functions, while Cellulose Derivatives continue to anchor standard compression and disintegration profiles; Gums And Gels are selected for moisture-sensitive matrices and specialty textures; Polyvinylpyrrolidone remains a versatile synthetic binder prized for solubility and process flexibility; Starch is employed for cost-effective granulation and disintegration purposes; and Sugars And Polyols are chosen where palatability, sweetness masking, or specific compactibility characteristics are required.
Looking through the lens of application, direct compression is favored where minimal wetting enhances stability and manufacturing speed, dry granulation is applied for moisture- and heat-sensitive actives or when roller compaction enhances flow, oral solid dosage forms encompass both capsule and tablet presentations with distinct binder selection criteria driven by disintegration and release profiles, and wet granulation is used to achieve uniformity and cohesion for high-dose or poorly compressible actives. In terms of form, dry binder formats are often preferred for feed-stock stability and simplicity in blend homogeneity, whereas liquid binder formats enable spray granulation, improved wettability, and bespoke binder distribution in complex processes. Finally, grade segmentation highlights that nutraceutical-grade binders often prioritize natural origin and label-friendly claims, while pharmaceutical-grade binders must meet stringent compendial standards, validated impurity profiles, and controlled manufacturing environments. Integrating these segmentation perspectives allows R&D and procurement teams to match binder attributes to process constraints and regulatory needs with greater precision.
Comparative regional analysis that links manufacturing hubs, regulatory environments, and sustainability priorities to binder sourcing and qualification strategies
Regional dynamics shape both access to raw materials and the regulatory frameworks that govern binder qualification. In the Americas, manufacturing clusters emphasize innovation in formulation science, proximity to large clinical and commercial markets, and a focus on nutraceuticals alongside pharmaceutical production, which drives demand for versatile binder portfolios and responsive local supply chains. Cross-border logistics within the region and established regulatory harmonization efforts support rapid qualification of alternative suppliers when needed.
Europe, Middle East & Africa present a heterogeneous regulatory landscape where European compendial standards coexist with varying regional regulatory capacities across the Middle East and Africa. This constellation demands sophisticated compliance strategies from both suppliers and manufacturers, including enhanced documentation, localized stability data packages, and adaptable quality systems. The region’s emphasis on sustainability and circularity is also influencing procurement preferences for bio-based and lower-impact binder options. Asia-Pacific continues to be a dominant source of raw material manufacturing and high-volume supply, with significant production capacity in several markets and ongoing investments in quality modernization. The region’s exporters are central to global supply chains, yet customers increasingly seek supplier transparency, enhanced quality certifications, and regional distribution buffers to manage geopolitical and trade policy risks.
How supplier strategies, technical service investment, and sustainability commitments are shaping competitive differentiation among binder excipient providers
Competitive dynamics among key industry players are characterized by a mix of consolidation, targeted innovation, and downstream integration. Leading suppliers are investing in application laboratories and technical service teams to offer co-development support, enabling faster route-to-market for new formulations and smoother supplier qualification. Others are pursuing backward integration or strategic partnerships with raw material providers to improve traceability and secure critical inputs, while some are expanding manufacturing footprints in strategic regions to reduce lead times and tariff exposure.
Innovation pipelines emphasize engineered excipient platforms that combine binder functionality with lubricity or disintegrant properties, reducing total excipient counts and simplifying validation packages. Several firms are enhancing their sustainability credentials through renewable feedstocks, solvent-free processing routes, and third-party environmental certifications. Quality systems and regulatory support services have become differentiators, with top performers offering comprehensive documentation suites, change-control roadmaps, and stability support to accelerate customer approvals. The competitive landscape therefore rewards companies that combine technical excellence, regulatory know-how, and supply chain agility to meet increasingly exacting customer expectations.
Practical and prioritized actions for formulation teams, procurement leaders, and executives to strengthen resilience, accelerate development, and align sustainability objectives
Industry leaders should prioritize a coordinated strategy that aligns formulation flexibility, supply chain resilience, and regulatory preparedness. First, R&D and procurement must jointly develop qualification plans that include second-source validation for critical binders and cross-functional acceptance criteria to facilitate rapid vendor switches when necessary. This collaborative approach reduces single-point failure risk and accelerates continuity planning.
Second, investments in excipient characterization and small-scale process modeling will pay dividends by de-risking scale-up and enabling more predictable performance when transitioning between production modes. Third, supply chain diversification should be pursued with an emphasis on near-term regional buffers, contractual clauses that address tariff volatility, and tiered inventory strategies that balance working capital with operational continuity. Fourth, sustainability and provenance claims should be substantiated with measurable KPIs and included in supplier scorecards to support corporate environmental goals and customer-facing differentiation. Finally, engage proactively with regulators and standards bodies when novel binder chemistries or sourcing strategies are contemplated, using pre-submission discussions and robust comparability datasets to minimize approval timelines. Implementing these recommendations will position organizations to respond to commercial and policy shocks while preserving formulation integrity and time-to-market.
A rigorous mixed-methods research design combining practitioner interviews, technical literature review, and expert validation to ensure robust and actionable binder excipient insights
The research underpinning this executive summary employed a mixed-methods approach designed to triangulate technical performance data, supply chain intelligence, and stakeholder perspectives. Primary inputs consisted of structured interviews with formulation scientists, procurement directors, quality assurance leads, and third-party manufacturing partners to capture operational constraints, supplier experiences, and decision criteria. Secondary research encompassed product literature, regulatory guidance documents, patent activity mapping, and peer-reviewed technical publications to build a robust evidence base on binder properties, processing behaviors, and innovation trajectories.
Data synthesis followed a layered validation process: initial findings were mapped against multiple independent sources to identify convergent themes, and key assertions were subsequently reviewed in expert panels comprised of practicing formulators and regulatory specialists. Segmentation and regional analyses were derived by aligning functional attributes of binder types and forms with known application demands and regional manufacturing capabilities. Limitations include the evolving nature of trade policy and the proprietary nature of some supplier technical data; to mitigate these constraints, the methodology emphasized transparency of sources and incorporated sensitivity checks to ensure that recommendations remain applicable across plausible operational scenarios.
A concise synthesis that ties formulation imperatives, procurement resilience, and regulatory alignment into strategic priorities for binder excipient decision-makers
The synthesis of technical, commercial, and regional intelligence reveals a clear strategic imperative: binder excipients must be evaluated as multifunctional, supply-sensitive components that materially influence product performance and operational resilience. Formulators should view binder selection as an integrated decision that accounts for process modality, regulatory demands, and end-user expectations, while procurement must embed scenario-based sourcing strategies to address tariff and geopolitical uncertainty. Suppliers that invest in technical service, sustainability, and regional capacity stand to differentiate themselves as trusted partners capable of supporting complex product portfolios.
In closing, organizations that proactively align formulation science, procurement strategy, and regulatory engagement will be better positioned to navigate the evolving landscape. By adopting robust qualification practices, diversifying sourcing options, and demanding higher transparency from suppliers, stakeholders can reduce risk, accelerate product timelines, and meet both commercial and sustainability objectives. The full report translates these conclusions into granular diagnostics and practical roadmaps that enable prioritized action across R&D, quality, and supply chain functions.
Note: PDF & Excel + Online Access - 1 Year
An authoritative framing of binder excipients importance that situates formulation performance, process robustness, and regulatory imperatives within contemporary pharmaceutical development
Binder excipients play a foundational role in the manufacture and performance of solid dosage pharmaceuticals and nutraceuticals, providing mechanical cohesion, process stability, and controlled disintegration behavior. Their selection and optimization influence tablet tensile strength, friability, dissolution kinetics, and manufacturability across granulation and compression operations. As formulation strategies and production paradigms evolve, binders are no longer ancillary inputs but critical enablers of downstream performance, packaging choices, and patient experience.
In parallel, material science advances and changing regulatory expectations have elevated the technical bar for binder selection. Modern binder development balances multifunctionality, compatibility with active pharmaceutical ingredients, and robustness under continuous and direct-compression processes. Quality by design approaches demand deeper characterization of binder particle size distribution, moisture sorption, and flow properties, while sustainability concerns prompt evaluation of renewable sources and manufacturing footprints. This introduction sets the context for understanding how binders contribute to product differentiation and supply chain dynamics across therapeutic and nutraceutical portfolios.
How technological modernization, regulatory scrutiny, and sustainability priorities are converging to redefine binder excipient functionality and supplier relationships
The landscape for binder excipients is undergoing transformative shifts driven by technological, regulatory, and sustainability pressures that are reshaping formulation and manufacturing practices. Adoption of continuous manufacturing and intensified processes has raised demand for excipients with predictable rheology and tighter functional tolerances, prompting suppliers to invest in advanced characterization and engineering of binder particles. Meanwhile, the growing emphasis on direct compression routes has accelerated interest in multifunctional binders that simplify formulations by reducing auxiliary excipient counts and enabling higher throughput.
Concurrently, regulatory agencies are increasing focus on supply chain transparency, excipient provenance, and risk-based control strategies. This has nudged manufacturers toward more rigorous supplier qualification, enhanced batch-to-batch traceability, and earlier engagement with regulators for novel excipient introduction. Sustainability goals have also reframed raw material sourcing: formulators and procurement teams are evaluating bio-based polymers, lower-energy processing routes, and supply partners with demonstrable commitments to reducing carbon and water intensity. Together, these forces are creating a market in which performance attributes, environmental credentials, and supply chain resilience are equally weighted in binder selection decisions.
Assessment of how United States tariff dynamics in 2025 have reshaped supply strategies, procurement behavior, and formulation risk management across the binder excipient value chain
Tariff policy developments in the United States during 2025 have introduced a new layer of complexity for organizations that source binder excipients internationally. Increased import duties and related administrative measures have magnified landed cost volatility and prompted procurement teams to reassess supplier matrices and contractual terms. The cumulative effect has been a renewed focus on supply chain resilience, with firms weighing options such as nearshoring, multi-sourcing, and strategic stocking to mitigate exposure to tariff-driven cost swings.
Beyond cost implications, tariffs have affected sourcing timelines and inventory strategies. Companies with just-in-time replenishment models faced pressures to extend lead times or secure local alternatives to avoid disruption. In parallel, suppliers in exporting markets adjusted commercial behaviors, including renegotiating long-term contracts and reconfiguring logistics to preserve competitiveness. Formulation groups responded by prioritizing binder chemistries that are available from a broader set of qualified vendors, reducing single-source dependency. Strategic procurement workstreams now routinely integrate tariff scenario planning into supplier scorecards, and cross-functional teams are coordinating with regulatory affairs to ensure that any vendor or material substitutions align with quality and compliance expectations.
Segmentation-informed synthesis of binder types, application pathways, form factors, and grade distinctions that elucidates formulation and procurement decision drivers
Segmentation-driven insights reveal where technical demand and commercial opportunity intersect across binder excipients. When analyzed by type, formulations increasingly rely on Alginates for specific controlled-release and mucoadhesive functions, while Cellulose Derivatives continue to anchor standard compression and disintegration profiles; Gums And Gels are selected for moisture-sensitive matrices and specialty textures; Polyvinylpyrrolidone remains a versatile synthetic binder prized for solubility and process flexibility; Starch is employed for cost-effective granulation and disintegration purposes; and Sugars And Polyols are chosen where palatability, sweetness masking, or specific compactibility characteristics are required.
Looking through the lens of application, direct compression is favored where minimal wetting enhances stability and manufacturing speed, dry granulation is applied for moisture- and heat-sensitive actives or when roller compaction enhances flow, oral solid dosage forms encompass both capsule and tablet presentations with distinct binder selection criteria driven by disintegration and release profiles, and wet granulation is used to achieve uniformity and cohesion for high-dose or poorly compressible actives. In terms of form, dry binder formats are often preferred for feed-stock stability and simplicity in blend homogeneity, whereas liquid binder formats enable spray granulation, improved wettability, and bespoke binder distribution in complex processes. Finally, grade segmentation highlights that nutraceutical-grade binders often prioritize natural origin and label-friendly claims, while pharmaceutical-grade binders must meet stringent compendial standards, validated impurity profiles, and controlled manufacturing environments. Integrating these segmentation perspectives allows R&D and procurement teams to match binder attributes to process constraints and regulatory needs with greater precision.
Comparative regional analysis that links manufacturing hubs, regulatory environments, and sustainability priorities to binder sourcing and qualification strategies
Regional dynamics shape both access to raw materials and the regulatory frameworks that govern binder qualification. In the Americas, manufacturing clusters emphasize innovation in formulation science, proximity to large clinical and commercial markets, and a focus on nutraceuticals alongside pharmaceutical production, which drives demand for versatile binder portfolios and responsive local supply chains. Cross-border logistics within the region and established regulatory harmonization efforts support rapid qualification of alternative suppliers when needed.
Europe, Middle East & Africa present a heterogeneous regulatory landscape where European compendial standards coexist with varying regional regulatory capacities across the Middle East and Africa. This constellation demands sophisticated compliance strategies from both suppliers and manufacturers, including enhanced documentation, localized stability data packages, and adaptable quality systems. The region’s emphasis on sustainability and circularity is also influencing procurement preferences for bio-based and lower-impact binder options. Asia-Pacific continues to be a dominant source of raw material manufacturing and high-volume supply, with significant production capacity in several markets and ongoing investments in quality modernization. The region’s exporters are central to global supply chains, yet customers increasingly seek supplier transparency, enhanced quality certifications, and regional distribution buffers to manage geopolitical and trade policy risks.
How supplier strategies, technical service investment, and sustainability commitments are shaping competitive differentiation among binder excipient providers
Competitive dynamics among key industry players are characterized by a mix of consolidation, targeted innovation, and downstream integration. Leading suppliers are investing in application laboratories and technical service teams to offer co-development support, enabling faster route-to-market for new formulations and smoother supplier qualification. Others are pursuing backward integration or strategic partnerships with raw material providers to improve traceability and secure critical inputs, while some are expanding manufacturing footprints in strategic regions to reduce lead times and tariff exposure.
Innovation pipelines emphasize engineered excipient platforms that combine binder functionality with lubricity or disintegrant properties, reducing total excipient counts and simplifying validation packages. Several firms are enhancing their sustainability credentials through renewable feedstocks, solvent-free processing routes, and third-party environmental certifications. Quality systems and regulatory support services have become differentiators, with top performers offering comprehensive documentation suites, change-control roadmaps, and stability support to accelerate customer approvals. The competitive landscape therefore rewards companies that combine technical excellence, regulatory know-how, and supply chain agility to meet increasingly exacting customer expectations.
Practical and prioritized actions for formulation teams, procurement leaders, and executives to strengthen resilience, accelerate development, and align sustainability objectives
Industry leaders should prioritize a coordinated strategy that aligns formulation flexibility, supply chain resilience, and regulatory preparedness. First, R&D and procurement must jointly develop qualification plans that include second-source validation for critical binders and cross-functional acceptance criteria to facilitate rapid vendor switches when necessary. This collaborative approach reduces single-point failure risk and accelerates continuity planning.
Second, investments in excipient characterization and small-scale process modeling will pay dividends by de-risking scale-up and enabling more predictable performance when transitioning between production modes. Third, supply chain diversification should be pursued with an emphasis on near-term regional buffers, contractual clauses that address tariff volatility, and tiered inventory strategies that balance working capital with operational continuity. Fourth, sustainability and provenance claims should be substantiated with measurable KPIs and included in supplier scorecards to support corporate environmental goals and customer-facing differentiation. Finally, engage proactively with regulators and standards bodies when novel binder chemistries or sourcing strategies are contemplated, using pre-submission discussions and robust comparability datasets to minimize approval timelines. Implementing these recommendations will position organizations to respond to commercial and policy shocks while preserving formulation integrity and time-to-market.
A rigorous mixed-methods research design combining practitioner interviews, technical literature review, and expert validation to ensure robust and actionable binder excipient insights
The research underpinning this executive summary employed a mixed-methods approach designed to triangulate technical performance data, supply chain intelligence, and stakeholder perspectives. Primary inputs consisted of structured interviews with formulation scientists, procurement directors, quality assurance leads, and third-party manufacturing partners to capture operational constraints, supplier experiences, and decision criteria. Secondary research encompassed product literature, regulatory guidance documents, patent activity mapping, and peer-reviewed technical publications to build a robust evidence base on binder properties, processing behaviors, and innovation trajectories.
Data synthesis followed a layered validation process: initial findings were mapped against multiple independent sources to identify convergent themes, and key assertions were subsequently reviewed in expert panels comprised of practicing formulators and regulatory specialists. Segmentation and regional analyses were derived by aligning functional attributes of binder types and forms with known application demands and regional manufacturing capabilities. Limitations include the evolving nature of trade policy and the proprietary nature of some supplier technical data; to mitigate these constraints, the methodology emphasized transparency of sources and incorporated sensitivity checks to ensure that recommendations remain applicable across plausible operational scenarios.
A concise synthesis that ties formulation imperatives, procurement resilience, and regulatory alignment into strategic priorities for binder excipient decision-makers
The synthesis of technical, commercial, and regional intelligence reveals a clear strategic imperative: binder excipients must be evaluated as multifunctional, supply-sensitive components that materially influence product performance and operational resilience. Formulators should view binder selection as an integrated decision that accounts for process modality, regulatory demands, and end-user expectations, while procurement must embed scenario-based sourcing strategies to address tariff and geopolitical uncertainty. Suppliers that invest in technical service, sustainability, and regional capacity stand to differentiate themselves as trusted partners capable of supporting complex product portfolios.
In closing, organizations that proactively align formulation science, procurement strategy, and regulatory engagement will be better positioned to navigate the evolving landscape. By adopting robust qualification practices, diversifying sourcing options, and demanding higher transparency from suppliers, stakeholders can reduce risk, accelerate product timelines, and meet both commercial and sustainability objectives. The full report translates these conclusions into granular diagnostics and practical roadmaps that enable prioritized action across R&D, quality, and supply chain functions.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
187 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rising demand for natural polymer binders derived from renewable resources for sustainable formulations
- 5.2. Increasing adoption of spray-dried starch as multifunctional binder in direct compression tablet processes
- 5.3. Growing focus on microcrystalline cellulose variants with enhanced compressibility in high-speed tablet manufacturing
- 5.4. Development of multifunctional coprocessed binder excipients to replace single-function binding agents in tablets
- 5.5. Integration of organic acid modified binder excipients to improve tablet disintegration and dissolution performance
- 5.6. Expansion of pharmaceutical dye-free and allergen-free binder formulations to meet evolving regulatory requirements
- 5.7. Advancement of binder excipient formulations enabling continuous manufacturing in pharmaceutical production lines
- 5.8. Surge in R&D for nanoengineered binder excipients to optimize drug release profiles in controlled release tablets
- 5.9. Emergence of predictive modeling software for binder performance to streamline formulation development and reduce trial failures
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Binders Excipients Market, by Type
- 8.1. Alginates
- 8.2. Cellulose Derivatives
- 8.3. Gums And Gels
- 8.4. Polyvinylpyrrolidone
- 8.5. Starch
- 8.6. Sugars And Polyols
- 9. Binders Excipients Market, by Form
- 9.1. Dry Binder
- 9.2. Liquid Binder
- 10. Binders Excipients Market, by Grade
- 10.1. Nutraceutical
- 10.2. Pharmaceutical
- 11. Binders Excipients Market, by Application
- 11.1. Direct Compression
- 11.2. Dry Granulation
- 11.3. Oral Solid Dosage
- 11.3.1. Capsule
- 11.3.2. Tablet
- 11.4. Wet Granulation
- 12. Binders Excipients Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Binders Excipients Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Binders Excipients Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. BASF SE
- 15.3.2. DuPont de Nemours, Inc.
- 15.3.3. Evonik Industries AG
- 15.3.4. Ashland Global Holdings Inc.
- 15.3.5. Roquette Frères S.A.
- 15.3.6. DFE Pharma GmbH & Co. KG
- 15.3.7. JRS PHARMA GmbH & Co. KG
- 15.3.8. Shin-Etsu Chemical Co., Ltd.
- 15.3.9. Dow Chemical Company
- 15.3.10. Colorcon, Inc.
- 15.3.11. Archer Daniels Midland Company
- 15.3.12. Cargill, Incorporated
- 15.3.13. Ingredion Incorporated
- 15.3.14. Kerry Group plc
- 15.3.15. Merck KGaA
- 15.3.16. Sigachi Industries Limited
- 15.3.17. Meggle Group GmbH
- 15.3.18. Avantor, Inc.
- 15.3.19. Lubrizol Corporation
- 15.3.20. Fuji Chemical Industries Co., Ltd.
- 15.3.21. SPI Pharma, Inc.
- 15.3.22. Asahi Kasei Corporation
- 15.3.23. Nippon Soda Co., Ltd.
- 15.3.24. Daicel Corporation
- 15.3.25. Matsutani Chemical Industry Co., Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
